Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Lawsuit Eligibility

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Legal Concerns

For decades, general health and science information has served as a foundational resource for public understanding of medical conditions and treatment options. This legacy context has empowered individuals to make informed decisions about their care, particularly when navigating complex therapeutic landscapes. Within this broad framework, discussions of medication safety and adverse effects have always been central, allowing patients and providers to weigh benefits against potential risks. As this informational heritage evolved, a specific area of concern emerged: the intersection of biologic therapies and neurological complications. One notable example involves the medication Tysabri, used in the management of certain chronic conditions, and its established association with Progressive Multifocal Leukoencephalopathy (PML), a serious brain infection. This connection has shifted the focus from general health awareness to a more targeted occupational exposure concern. The pivot occurs when considering how patients who have been exposed to Tysabri and subsequently developed PML may seek legal recourse. The question of eligibility for a Tysabri Progressive Multifocal Leukoencephalopathy lawsuit arises from this precise exposure history. Thus, the transition from broad health literacy to a specific legal inquiry is grounded in the documented risk profile of the drug, moving from general education to the practical implications of adverse outcomes for affected individuals.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration requires a boxed warning on the Tysabri label, highlighting that the drug increases PML risk and that patients must be monitored closely (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive decline, vision loss, and coordination problems. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition is often fatal, and survivors frequently suffer permanent disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML Development in Tysabri Patients

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks lymphocyte adhesion and migration into the central nervous system, which reduces inflammation but also impairs immune surveillance. This allows latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label notes that PML typically occurs only in immunocompromised patients, and Tysabri-induced immune suppression creates a permissive environment for the virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two with multiple sclerosis who had received Tysabri plus interferon beta-1a for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance has identified many additional cases.

Legal Considerations for Tysabri-Related PML

The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The label includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to monitor patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, critics argue that these measures may not fully inform patients of the magnitude of risk, particularly for those with multiple risk factors. The label states that physicians should consider expected benefit versus risk when initiating treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Some patients may not have been adequately counseled about the cumulative risk over time or the implications of anti-JCV antibody status. For patients who develop PML after Tysabri exposure, legal eligibility for a lawsuit typically depends on several factors. First, there must be documented evidence of PML diagnosis following Tysabri treatment, with a reasonable temporal relationship. The timeline between exposure and harm is critical: PML can occur after varying durations of therapy, but risk increases with longer use, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Second, plaintiffs must show that inadequate warnings or failure to monitor contributed to their injury. This may involve demonstrating that healthcare providers did not properly assess risk factors or that the drug manufacturer did not provide sufficient information about PML risk.

Eligibility Criteria for a Tysabri PML Lawsuit

Attorney considerations for affected patients include the need to gather medical records documenting Tysabri prescriptions, anti-JCV antibody testing results, and PML diagnosis. Legal claims may allege failure to warn, negligence, or product liability. The boxed warning and restricted distribution program may be used by defendants to argue that risks were adequately communicated. However, plaintiffs may counter that the warning was insufficient given the severity of PML and the availability of risk mitigation strategies, such as regular MRI screening or discontinuation after two years. Patients who have suffered PML after Tysabri use should consult with an attorney experienced in pharmaceutical litigation. Eligibility for a lawsuit requires establishing that the drug caused the injury and that the manufacturer failed to provide adequate warnings. The presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use are key factors in assessing individual risk and legal merit (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Given the devastating consequences of PML, legal action may provide compensation for medical expenses, lost income, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA requires a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri patients?

Diagnosis involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal claims can be made for Tysabri-related PML?

Legal claims may include failure to warn, negligence, or product liability. Plaintiffs must show that inadequate warnings or failure to monitor contributed to their injury.

What evidence is needed for a Tysabri PML lawsuit?

Medical records documenting Tysabri prescriptions, anti-JCV antibody testing, and PML diagnosis are essential. A reasonable temporal relationship between exposure and harm must be established.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Label (DailyMed)

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.